Xentuzumab (BI836845) is a recombinant human monoclonal antibody specifically designed to target and neutralize the insulin-like growth factors IGF1 and IGF2. By binding to these ligands, Xentuzumab effectively inhibits their role in promoting cellular growth and proliferation. Additionally, this antibody suppresses the activation of AKT, a critical kinase in the PI3K/AKT signaling pathway, further impeding oncogenic signaling. This dual mechanism of action makes Xentuzumab a valuable tool in research focused on cancer biology, particularly in studies exploring the regulation of growth factor-mediated signal transduction and its impact on cellular behaviors.
Xentuzumab (BI836845) is a recombinant human monoclonal antibody specifically designed to target and neutralize the insulin-like growth factors IGF1 and IGF2. By binding to these ligands, Xentuzumab effectively inhibits their role in promoting cellular growth and proliferation. Additionally, this antibody suppresses the activation of AKT, a critical kinase in the PI3K/AKT signaling pathway, further impeding oncogenic signaling. This dual mechanism of action makes Xentuzumab a valuable tool in research focused on cancer biology, particularly in studies exploring the regulation of growth factor-mediated signal transduction and its impact on cellular behaviors.
Targets
IGF1, IGF2
Product Information
Catalog Num
AT0499
Molecular Weight
143700
CAS Number
1417158-65-6
Isotype
Human IgG1 lambda2, Isotype Control
Synonyms
BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
